Spyre Therapeutics
SYRE----
Spyre Therapeutics (SYRE)
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) a...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Spyre Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 24, 2026Price forecast
$103.933.89%
Forecast & RatingStrong buy
17analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 2 days ago, 08:25 PM
Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim
- Market Beat · Jul 13 at 07:06 AM
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Expected to Rise, Mizuho Analyst Says
- PUBT · Jul 2 at 08:32 PM
Spyre Therapeutics CEO Cameron Turtle sells common shares worth $1.32 million
- Unusual Whales · Jul 2 at 03:12 PM
Spyre Therapeutics Announces Grants of Inducement Awards
- PUBT · Jul 2 at 03:06 PM
Spyre Therapeutics grants inducement equity awards of 58,843 stock options, 2,134 RSUs to new hires
- Simplywall · Jul 2 at 10:51 AM
Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative
